<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02710513</url>
  </required_header>
  <id_info>
    <org_study_id>ProAliFun_6.5_CE4372</org_study_id>
    <nct_id>NCT02710513</nct_id>
  </id_info>
  <brief_title>ProAliFun_6.5_Health Effects of a Functional Pasta Enriched With Barley Beta-glucans on Healthy Subjects</brief_title>
  <acronym>ProAliFun65</acronym>
  <official_title>Technological and Clinical Innovative Protocols for the Production of Functional Foods - 6.5 (ProAliFun65)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliero-Universitaria Consorziale</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Bari</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Azienda Ospedaliero-Universitaria Consorziale</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the healthy properties of a dietary intervention
      based on an innovative pasta enriched with prebiotic fibers (barley beta-glucans).

      The hypothesis is that the gut microbiota and metabolome, the nutritional status, the
      redox/subclinical inflammation parameters and the markers of cardiovascular risk may improve
      in healthy subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical trial is a prospective pilot study, lasting 4 months. A target number of 30
      healthy individuals meeting inclusion and exclusion criteria, assessed at enrollment, and
      which have signed the informed consent, will be recruited.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in non-HDL cholesterol</measure>
    <time_frame>at the end of the intervention period (2 months)</time_frame>
    <description>Confirmation of beta-glucans properties in reduction of total and LDL cholesterol</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effects on gut microbiota SCFA modulation</measure>
    <time_frame>at the end of the intervention period (2 months)</time_frame>
    <description>Measurement of fecal levels of short-chain fatty acids (acetate, propionate, butyrate)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects on gut microbiota pCS modulation</measure>
    <time_frame>at the end of the intervention period (2 months)</time_frame>
    <description>Measurement of circulating levels of p-cresyl sulphate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects on gut microbiota IS modulation</measure>
    <time_frame>at the end of the intervention period (2 months)</time_frame>
    <description>Measurement of circulating levels of indoxyl sulphate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects on Flow-mediated dilation (FMD)</measure>
    <time_frame>at the end of the intervention period (2 months)</time_frame>
    <description>Measurement of beta-glucans effect on endothelial function through FMD</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Beta-glucans</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 months run-in period (Mediterranean Diet-based dietary scheme including a daily supply of 100 g of normal pasta) + 2 months intervention period (Mediterranean Diet-based dietary scheme including a daily supply of 100 g of functional pasta providing 3 g of beta-glucans/day)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Beta-glucans</intervention_name>
    <description>2 months Mediterranean Diet-based free diet (run-in) + 2 months Mediterranean Diet-based free diet with a daily supplementation of 100 g of beta-glucans pasta (intervention). Medical visits, dietary counselling with food frequency questionnaires administration, blood, urine and feces collection were performed before (T0) and after (T2) the two months of beta-glucans intervention.</description>
    <arm_group_label>Beta-glucans</arm_group_label>
    <other_name>Functional pasta enriched with barley beta-glucans</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy subjects

          -  aged between 30 and 70 years

          -  BMI between 18.5 and 24.9

          -  omnivorous diet

          -  informed consent signed

        Exclusion Criteria:

          -  diabetes type 2

          -  urine protein &gt; 1g/24h

          -  antibiotics and probiotics administration by 15 days before the enrollment

          -  gastrointestinal, celiac, inflammatory systemic and chronic liver diseases

          -  recent diagnosis of cancer

          -  corticosteroid or immunosuppressive therapies

          -  previous major acute cardiovascular pathologies (heart attack, cerebral ictus)

          -  hyperlipidemia

          -  consume of alcohol

          -  psychiatric diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Loreto Gesualdo, MD Full Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Head of the Nephrology, Dialysis and Transplantation Unit &quot;Aldo Moro&quot; University of Bari Azienda Ospedaliero-Universitaria Consorziale &quot;Policlinico&quot;</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AOUC &quot;Policlinico&quot;</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2016</study_first_submitted>
  <study_first_submitted_qc>March 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2016</study_first_posted>
  <last_update_submitted>March 16, 2016</last_update_submitted>
  <last_update_submitted_qc>March 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>beta-glucans</keyword>
  <keyword>gut microbiota</keyword>
  <keyword>p-cresyl sulphate (pCS)</keyword>
  <keyword>indoxyl sulphate (IS)</keyword>
  <keyword>short-chain fatty acid (SCFA)</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

